The company elects a new board of directors and the board of supervisors to appoint a new management team
Release time:
2020-08-14
Company elected a new board of directors and board of supervisors
to appoint a new management team
. News from our newspaper 11# October 16 , the company held the first extraordinary general meeting of shareholders in 2017 to consider and pass the "Proposal on the Full Change of Board of Directors" and the "Proposal on the Full Change of Board of Supervisors". Election of a new board of directors and board of supervisors. At the meeting of
, candidates for directors were voted one by one by a combination of on-site registered voting and online voting. Jiang Xiaomeng, Du Zihong, Yu Jianhong, Huang Sujian, Liu Bo, Zhang Guoping, Huang Congyun, Sun Hongbin and Shi Ximin were elected as directors of the 10th board of directors of the company, of which Huang Congyun, Sun Hongbin and Shi Ximin were independent directors. At the meeting of
, candidates for supervisors were voted one by one by a combination of on-site registered voting and online voting, and Chen Tianci, Lu Ruimei and Shi Fu were elected as supervisors of the ninth board of supervisors of the company. Prior to this, the company's trade union held an enlarged meeting of the trade union committee to elect Qin Xuping and Jin Huazhong as employee representative supervisors of the ninth board of supervisors.
On the same day, the company's tenth board of directors held its first meeting and elected Jiang Xiaomeng as the chairman of the tenth board of directors.
elected Jiang Xiaomeng, Du Zihong, Huang Sujian, Sun Hongbin and Shi Ximin as members of the Strategy Committee of the 10th Board of Directors, and Jiang Xiaomeng as chairman of the Strategy Committee.
elected Shi Ximin, Huang Congyun and Jiang Xiaomeng as members of the Audit Committee of the 10th Board of Directors and Shi Ximin as chairman.
elected Sun Hongbin, Huang Congyun, and Jiang Xiaomeng as members of the Nomination Committee of the 10th Board of Directors, and Sun Hongbin as the chairman.
elected Huang Congyun, Shi Ximin and Du Zihong as members of the Remuneration and Evaluation Committee of the 10th Board of Directors, and Huang Congyun as the chairman.
The board of directors appointed Yu Jianhong as the general manager of the company, Huang Jinlong, Zhang Fengliang and Xiang Chongping as the deputy general managers of the company, and Zhu Jianwei as the secretary of the board of directors of the company. Lan Xiaolong was appointed as the company's chief financial officer, Liu Lisu as the company's audit office director and Zhou Hengbin as the company's securities affairs representative.
On the same day, the ninth board of supervisors of the group company held its first meeting and elected Chen Tianci as the chairman of the ninth board of supervisors of the company by written voting. (Zhou Hengbin)
More information
Publicity of Environmental Protection Acceptance for Completion of Kiln End Flue Gas Desulfurization Project of daye peak cement co., ltd. According to the requirements of the Interim Measures for Environmental Protection Acceptance for Completion of Construction Projects (No.4 [2017] of the State Environmental Regulations) issued by the Ministry of Environmental Protection, the environmental protection acceptance information of "Kiln End Flue Gas Desulfurization Project" of daye peak cement co., ltd. is now publicized. Basic Information of 1. Project Project Name: Kiln End Flue Gas Desulfurization Project Construction Unit: daye Jianfeng Cement Co., Ltd. Project Construction Location: Yongguang Village, Baoan Town, daye city, nature of the project in the existing plant area of daye Jianfeng Cement Co., Ltd.: The construction content of the technological transformation project is: This technological transformation project is mainly to build a wet desulfurization system for kiln end gas of the company's existing 4000t cement clinker production line, adopting limestone-gypsum wet flue gas desulfurization process. The project covers a total area of 500 m2, with a new construction area of about 450 m2. It mainly builds desulfurization complex building, flue gas system, SO2 absorption system, limestone powder conveying and limestone slurry preparation system, process water system, gypsum dehydration system and supporting pipelines. Power supply, water supply, compressed air and other public works rely on the existing plant. Total investment and environmental protection investment: the total investment of the project is 10.37 million yuan, all of which are environmental protection investment. The project was entrusted to Huangshi Yangtze River Environmental Engineering Design and Research Institute to carry out environmental impact assessment in September 2017. On November 16, 2017, Daye Municipal Environmental Protection Bureau issued a reply with YEHAN [2017] No. 354. Implementation of 2. environmental protection measures The scope of this acceptance is the flue gas desulfurization system and supporting facilities at the end of the kiln. (1) Exhaust gas pollution
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Spike New Drug Approved for Registration
On April 16, Jianfeng Pharmaceutical Company received the approval and issuance of Olopatadine Hydrochloride Eye Drops "Drug Registration Approval" (approval number: 2019S00296) approved by the State Drug Administration. Olopatadine hydrochloride eye drops is mainly used to treat the signs and symptoms of allergic conjunctivitis. It is a mast cell stabilizer and a relatively selective histamine H1-receptor antagonist. It can inhibit type I immediate allergic reactions in vivo and in vitro experiments. At present, the product has been included in the "National Basic Medical Insurance, Work Injury Insurance and Maternity Insurance Drug Catalog (2017 Edition)" and classified as Class B. According to the relevant data of IMS database, in 2018, the global sales of olopatadine hydrochloride eye drops were about 0.37 billion US dollars, and the sales in China were about 10.232 million US dollars. Spike Pharmaceuticals already has the corresponding production line, this time to obtain the registration approval, marking Spike Pharmaceuticals has the qualification to carry out the production and sales of olopatadine hydrochloride eye drops, will further enrich the product line of Spike Pharmaceuticals, help to enhance the competitiveness of the company's pharmaceutical business. (Xia Yingpin)
2020
07-31
Contact Us
No. 88 Wujiang East Road, Jinhua City, Zhejiang Province, China
Tel: +86-579-82326868
Fax : +86-579-82324666
©2023 Zhejiang Jianfeng Group Co., Ltd. Powered by: www.300.cn SEO Business License
SAF Coolest v1.2 设置面板 SHJSS-AHDB-FSSQE-ZSW
无数据提示
Sorry, the current column has no content !
You can view other columns or return to Home Page